- Patent Title: Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
-
Application No.: US15703126Application Date: 2017-09-13
-
Publication No.: US10688180B2Publication Date: 2020-06-23
- Inventor: Robert F. Graziano , Ashok K. Gupta , Su Young Kim , Jon Wigginton , Pascale Andre
- Applicant: BRISTOL-MYERS SQUIBB COMPANY , Innate Pharma
- Applicant Address: US NJ Princeton FR Marseilles
- Assignee: BRISTOL-MYERS SQUIBB COMPANY,INNATE PHARMA
- Current Assignee: BRISTOL-MYERS SQUIBB COMPANY,INNATE PHARMA
- Current Assignee Address: US NJ Princeton FR Marseilles
- Agency: Nelson Mullins Riley & Scarborough LLP
- Agent Jane E. Remillard, Esq.; Jeanne M. DiGiorgio, Esq.
- Main IPC: C07K16/00
- IPC: C07K16/00 ; C07K16/30 ; C07K16/40 ; A61K39/00 ; A61K39/395 ; C07K16/28
Abstract:
Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.
Public/Granted literature
- US20180117147A1 COMBINATION OF ANTI-KIR AND ANTI-CTLA-4 ANTIBODIES TO TREAT CANCER Public/Granted day:2018-05-03
Information query
